In case you missed the myelodysplastic syndromes roundtable at the 2023 American Society of Hematology Annual Meeting, Drs. Hana Safah, Jamile Shammo, Andrew Brunner, and Tiffany Tanaka cover a study that compared luspatercept and epoetin alfa in myelodysplastic syndromes. Watch the full roundtable: https://buff.ly/3NSI9d8
Heme Today’s Post
More Relevant Posts
-
In this roundtable discussion at the 65th American Society of Hematology Annual Meeting & Exposition, Drs. Hana Safah, Jamile Shammo, Andrew Brunner, and Tiffany Tanaka share their outlook for the future of myelodysplastic syndromes research and treatments. Watch here: https://buff.ly/4aV7vB8
-
-
Executive Vice-President and Chief Medical Officer, CLL Society, Inc., a 501c3 dedicated to the unmet needs of the chronic lymphocytic community (CLL)
Should be an informative webinar for patient and doctor alike who are invested in the latest research from ASH 2023 on CLL/SLL
Our ASH 2023 Comes to You webinar is one week away on Jan. 26th! Join CLL expert Dr. Nicole Lamanna and Dr. Brian Koffman as they discuss important CLL research and clinical trial data that was presented at the American Society of Hematology (ASH) Annual Meeting that took place in December 2023. Learn more and register at: https://bit.ly/3ROI3nQ
-
-
Dynamic Service Leader||Data Science Enthuist||Ready to make positive impact in healthcare||Medical Content Creator||Connecting Student to Scholarship and Funding||
🔬Amzing Notes About Hematology Review♥️ ✔️Do Share It. 🤔What You Will Learn: 📌Literally Everything About Hematology(From Blood Collection to the Each indices Significance) #knowledgesharing #Laboratoryprofessional #BiomedicalEngineers
-
Have you read our recent Q&A with our Reach-the-World Fellow Mark Allan Lim? Learn more about his interest in improving the field of hematology in the Philippines here: https://lnkd.in/eqecTerN
-
-
NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology
-
-
How can your laboratory help reduce unnecessary complications for newly diagnosed Multiple Myeloma patients? Find out how from Prof. Guy Pratt who discusses how your laboratory can help guide blood test requesting and appropriate hematology referral. Download our case studies from hospitals in the United Kingdom, United States and Spain by here: https://hubs.li/Q02phTNn0
-
-
The American Journal of Hematology recently published the results of a phase II study of BTK inhibitor orelabrutinib in patients with ITP. “The phase 2 study provides compelling evidence for the potential of orelabrutinib as a safe and effective therapy for patients with ITP. Further investigation through larger, randomized, placebo-controlled trials is warranted to definitively confirm these findings and establish orelabrutinib as a valuable treatment option for ITP management，” said Professor Ming Hou, the leading PI. Read more: https://lnkd.in/eXSyjcVD Full paper is here: https://lnkd.in/evmzBApi
-
-
📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy
-
-
Unlock the secrets of hematology staining techniques with our latest blog post on the Wright-Giemsa stain! Perfect for laboratory professionals and students, this guide provides step-by-step instructions to help you achieve precise and accurate results 🔬🎨 Dive into the details here: https://bit.ly/3ycvOvL #WrightGiemsa #LabTutorial #HardyDiagnostics
-
HemaTopics are HemaSphere publications focusing on hot hematology topics including recent research developments, updates on diagnosis and treatment, policy and guidelines news, and more. This week we focus on the latest HemaTopic by Scientific Editor Charles de Bock which discusses a recent study from the Ross Levine Lab, which provides a strong rationale for the ongoing development of more potent JAK2 inhibitors. https://bit.ly/43KMqWP